17 November 2026 Sofdra® safety and benefit-risk profile reaffirmed in major American dermatology journal Key Highlights • An article appearing in The Journal of the American Academy of Dermatology (JAAD) reports a favourable risk-benefit profile of Sofdra® • Peer-reviewed brief report...
Sofdra safety and benefit-risk profile reaffirmed
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Botanix Pharmaceuticals Limited has announced the reaffirmation of the safety and benefit-risk profile of Sofdra, as reported in a major American dermatology journal. The peer-reviewed article analyzed adverse events related to Sofdra from a specific period and found them consistent with the known safety profile of the product. The publication highlights that no unexpected adverse events were identified, reinforcing confidence in Sofdra's performance. Botanix's CEO expressed encouragement regarding the transparent reporting of real-world safety data for Sofdra.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Sofdra receives the International Hyperhidrosis Society Seal
- Notification of cessation of securities - BOT
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - BOT
- Botanix Q1 FY27 Investor Update Webinar Presentation
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals